Compare Mongodb Inc (MDB) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mongodb Inc vs Merck & Co., Inc. — how do they compare? Mongodb Inc trades at $440.1 (market cap $35.32B), while Merck & Co., Inc. trades at $133.44 (market cap $321.77B). The key difference: Merck & Co., Inc. is far larger — about 9.1× Mongodb Inc's market cap, and Merck & Co., Inc. pays a 2.61% dividend while Mongodb Inc pays none. Which is the better fit depends on your goals.
| MDB | MRK | |
|---|---|---|
Market Cap | $35.32B | $321.77B |
Sector | Technology | Health |
52-Week High | $440.25 | $131.84 |
52-Week Low | $204.37 | $77.60 |
Enterprise Value | $32.93B | $368.53B |
Dividend Yield | — | 2.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MongoDB (MDB) trades at $439.54, up 5.49% on the day. The stock exhibits a bullish technical trend, with moving averages and overall signals supporting a buy stance, though oscillators show mixed signals. Fundamentally, revenue growth is strong, reaching $2.01B in 2025, but the company remains unprofitable with a net income margin of -1.12%. Recent earnings have consistently beaten expectations, and analyst sentiment is overwhelmingly positive with 81.81% buy ratings.
The outlook for MDB is optimistic due to robust revenue growth and AI-driven demand, but risks include persistent losses and high valuation multiples. The consensus price target of $404.30 suggests potential downside from current levels, indicating caution despite bullish sentiment. Investors should weigh growth prospects against profitability challenges and market volatility.
Merck & Co. (MRK) trades at $133.64, up 2.09% today, with a bullish technical signal from moving averages and strong institutional buying interest. The company reported solid earnings beats in recent quarters, with Q3 2026 EPS expected at $2.27. Revenue for 2025 reached $65.01B, and net income was $18.25B, though the P/E ratio of 104.34 suggests high valuation expectations. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline.
Outlook: MRK's growth is supported by strategic acquisitions and a dominant oncology franchise, but risks include high valuation multiples and competitive pressures. The consensus price target of $140.36 implies modest upside, with 68% of analysts rating it a Buy. Investors should monitor execution on the Terns integration and Q3 earnings results for catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mongodb Inc
Founded in 2007, MongoDB is a document-oriented database with nearly 33,000 paying customers and well past 1.5 million free users. MongoDB provides both licenses as well as subscriptions as a service for its NoSQL database. MongoDB's database is compatible with all major programming languages and is capable of being deployed for a variety of use cases.
Read more on MDB →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
